Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type-1 diabetes; a randomized controlled trial

Hermanides, J., Nørgaard, K., Bruttomesso, D., Mathieu, C., Frid, A., Dayan, Colin Mark ORCID: https://orcid.org/0000-0002-6557-3462, Diem, P., Fermon, C., Wentholt, I. M. E., Hoekstra, J. B. L. and DeVries, J. H. 2011. Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type-1 diabetes; a randomized controlled trial. Diabetic Medicine 28 (10) , pp. 1158-1167. 10.1111/j.1464-5491.2011.03256.x

Full text not available from this repository.

Abstract

Aims To investigate the efficacy of sensor-augmented pump therapy vs. multiple daily injection therapy in patients with suboptimally controlled Type 1 diabetes. Methods In this investigator-initiated multi-centre trial (the Eurythmics Trial) in eight outpatient centres in Europe, we randomized 83 patients with Type 1 diabetes (40 women) currently treated with multiple daily injections, age 18–65 years and HbA1c≥ 8.2% (≥ 66 mmol/mol) to 26 weeks of treatment with either a sensor-augmented insulin pump (n = 44) (Paradigm® REAL-Time) or continued with multiple daily injections (n = 39). Change in HbA1c between baseline and 26 weeks, sensor-derived endpoints and patient-reported outcomes were assessed. Results The trial was completed by 43/44 (98%) patients in the sensor-augmented insulin pump group and 35/39 (90%) patients in the multiple daily injections group. Mean HbA1c at baseline and at 26 weeks changed from 8.46% (sd 0.95) (69 mmol/mol) to 7.23% (sd 0.65) (56 mmol/mol) in the sensor-augmented insulin pump group and from 8.59% (sd 0.82) (70 mmol/mol) to 8.46% (sd 1.04) (69 mmol/mol) in the multiple daily injections group. Mean difference in change in HbA1c after 26 weeks was −1.21% (95% confidence interval −1.52 to −0.90, P < 0.001) in favour of the sensor-augmented insulin pump group. This was achieved without an increase in percentage of time spent in hypoglycaemia: between-group difference 0.0% (95% confidence interval −1.6 to 1.7, P = 0.96). There were four episodes of severe hypoglycaemia in the sensor-augmented insulin pump group and one episode in the multiple daily injections group (P = 0.21). Problem Areas in Diabetes and Diabetes Treatment Satisfaction Questionnaire scores improved in the sensor-augmented insulin pump group. Conclusions Sensor augmented pump therapy effectively lowers HbA1c in patients with Type 1 diabetes suboptimally controlled with multiple daily injections.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: continuous blood glucose monitoring, continuous subcutaneous insulin infusion, randomized controlled trial, Type 1 diabetes
Publisher: Wiley
ISSN: 0742-3071
Last Modified: 20 Oct 2022 07:56
URI: https://orca.cardiff.ac.uk/id/eprint/26985

Citation Data

Cited 143 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item